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Introduction: Activation of the mTOR pathway has been linked to the cytopathology and epileptogenicity of
malformations, specifically Focal Cortical Dysplasia (FCD) and Tuberous Sclerosis (TSC). Experimental and clinical
trials have shown than mTOR inhibitors have anti-epileptogenic effects in TS. Dysmorphic neurones and balloon
cells are hallmarks of FCDIIb and TSC, but similar cells are also occasionally observed in other acquired epileptogenic
pathologies, including hippocampal sclerosis (HS) and Rasmussen’s encephalitis (RE). Our aim was to explore mTOR
pathway activation in a range of epilepsy-associated pathologies and in lesion-negative cases.
Results: 50 epilepsy surgical pathologies were selected including HS ILAE type 1 with (5) and without dysmorphic
neurones (4), FCDIIa (1), FCDIIb (5), FCDIIIa (5), FCDIIIb (3), FCDIIId (3), RE (5) and cortex adjacent to cavernoma (1).
We also included pathology-negative epilepsy cases; temporal cortex (7), frontal cortex (2), paired frontal cortical
samples with different ictal activity according to intracranial EEG recordings (4), cortex with acute injuries from electrode
tracks (5) and additionally non-epilepsy surgical controls (3). Immunohistochemistry for phospho-S6 (pS6) ser240/244 and
ser235/236 and double-labelling for Iba1, neurofilament, GFAP, GFAPdelta, doublecortin, and nestin were performed.
Predominant neuronal labelling was observed with pS6 ser240/244 and glial labelling with pS6 ser235/236 in all
pathology types but with evidence for co-expression in a proportion of cells in all pathologies. Intense labelling
of dysmorphic neurones and balloon cells was observed in FCDIIb, but dysmorphic neurones were also labelled
in RE and HS. There was no difference in pS6 labelling in paired samples according to ictal activity. Double-labelling
immunofluorescent studies further demonstrated the co-localisation of pS6 with nestin, doublecortin, GFAPdelta in
populations of small, immature neuroglial cells in a range of epilepsy pathologies.
Conclusions: Although mTOR activation has been more studied in the FCDIIb and TSC, our observations
suggest this pathway is activated in a variety of epilepsy-associated pathologies, and in varied cell types including
dysmorphic neurones, microglia and immature cell types. There was no definite evidence from our studies to suggest
that pS6 expression is directly related to disease activity.
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Dysmorphic neurones (DN) and balloon cells (BC) with
astroglial features are the cytological hallmarks of focal
cortical dysplasia (FCD) type IIb [1]. Similar cell types are
also seen in cortical lesions of tuberous sclerosis (TSC)
[2]. In both pathologies, mammalian target of rapamycin
(mTOR) pathway activation has been demonstrated [3-6],* Correspondence: m.thom@ucl.ac.uk
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unless otherwise stated.possibly representing a primary pathogenic mechanism
and a potential target for new treatment approaches [7].
Immunohistochemical confirmation of phosphorylated
downstream proteins in the mTOR pathway, particularly
the ribosomal protein phospho S6 (pS6), has become a
useful laboratory investigation in these pathologies.
mTOR regulates many critical physiological processes
governing cell survival, protein and lipid synthesis,
proliferation, metabolism, autophagy and cell death in
adult and developing neural tissues [8-10,7,4] with recent
investigations demonstrating how mTOR deregulation
could directly influence the cytopathology of FCD [11].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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morphology have been documented in the context of ac-
quired epilepsy-associated pathologies, including hippo-
campal sclerosis (HS) [12-16] and Rasmussen’s encephalitis
(RE) [17-19]. In some cases, the differential diagnosis with
FCDIIb is raised by such cytopathological alterations, and
the implementation of mTOR activation markers could be
considered as an adjunct diagnostic test. Recent studies,
however, have demonstrated mTOR pathway activation in
HS in epilepsy [20,21], suggesting that it may not be a spe-
cific biomarker for FCDIIb or TSC alone.
In this study we explored the mTOR pathway activa-
tion, through the pattern and cellular distribution of pS6
labelling, in a wide range of pathologies associated with
drug-resistant epilepsy. We demonstrate immunoreactiv-
ity associated with ‘dysplasia-like’ cytopathological changes,
in reactive processes, as well as in varied mature and im-
mature neuronal and glial cell types.
Materials and methods
Case selection
Consent was obtained from patients for use of tissue in
research and the project has ethical approval (NRES -
National Research Ethics Service 12SC0669). 45 patients
who had undergone epilepsy surgery were selected from
the databases of the Epilepsy Society Brain and Tissue
Bank at UCL Institute of Neurology. The range of patholo-
gies studied is detailed in Table 1 with patient demographics.
They included samples from 32 cases representative of
lesional epileptogenic pathologies and 18 samples with
no specific epileptogenic lesion; in five patients, more
than one tissue sample was used representing lesional and
extra-lesional tissue. Three non-epilepsy surgical control
samples were included. All epilepsy patients had under-
gone neurosurgery for the management of drug-resistant
epilepsy. The pathological criteria for HS and FCD types
were based on the current International League Against
Epilepsy (ILAE) classifications [22,1].
Lesional cases included patients with mesial temporal
lobe epilepsy (mTLE) and HS ILAE type 1 with (n = 5)
or without (n = 4) additional dysplasia-like cytopathological
changes, including prominent dysmorphic, neurofilament-
positive neuronal cells in CA4 and CD34-positive BC-like
astrocytes in the dentate gyrus as previously described
[15,14,13,12] (Figure 1A). FCD was represented by type IIa
(n = 1), type IIb (n = 5), type IIIa (dysplasia associated with
HS; n = 5), type IIIb (dysplasia associated with dysembryo-
plastic neuroepithelial tumours (DNT)/CD34-positive long-
term epilepsy-associated tumours (LEAT); n = 3), type IIId
(dysplasia associated with an early infarct; n = 3) and a caver-
noma with florid adjacent reactive gliosis (n = 1). In FCDIIb
cases TSC was excluded clinically. We included resections
from patients with a clinical and radiological diagnosis com-
patible with RE (n = 5) who had undergone either diagnosticbiopsy or therapeutic neurosurgical procedure. The stages of
inflammatory activity and scarring varied both within and
between cases, as detailed in Table 1, and in two cases
with RE, cortical neurones appeared hypertrophic and
dysmorphic.
Control groups with no epileptogenic lesions in-
cluded epilepsy patients who had undergone intracranial
EEG monitoring where two separate samples were avail-
able from grid or electrode sites according to regional
differences in ictal activity (n = 4), as detailed in Table 1.
We also included a further pathology-negative group (n = 5)
where only localised acute cortical injuries were identified
within the tissue specimens following previous depth elec-
trode insertion for intracranial EEG monitoring (8 to 10 days
prior to tissue resection), as previously studied [23,24]. Fur-
ther control groups included surgical cortical resections
from patients with epilepsy, but no cortical injuries, or
lesional pathology (n = 9), and from patients without epi-
lepsy which represented marginal normal cortex to a neo-
plasm (n = 3).
Immunohistochemistry
For the demonstration of pS6, we utilised two antibodies
recognising different phosphorylation sites of pS6: ser240/
244 specific for mTORC1 pathway, and ser 235/236 which
is a phosphorylation site that may be mTOR-independent
through Ras-MAPK pathway [25]. For this purpose, 5 μm
thickness formalin-fixed, paraffin-embedded brain sec-
tions of each case were processed through xylene and
graded alcohols before immersion in a solution with 0.9%
hydrogen peroxide for 15 minutes. Sections were micro-
waved in unmasking buffer (H-3301; Vector Laboratories
Inc., USA) at full power for 12 minutes, and cooled for
20 minutes. Sections were blocked using 2.5% normal horse
serum (Vector Lab, Peterborough, UK) for 20 minutes be-
fore incubation in a solution containing anti-phospho-S6
ser240/244 (1:1000, #5364, Cell Signaling Technology, Inc.,
Danvers, MA, USA) or ser235/236 (1:150, #4857, Cell Sig-
naling Technology, Inc.) overnight at 4ºC. For RE cases,
immunolabelling with HLADR (1:100, Monoclonal, Mouse
HLA-DP, DQ, DR Ag, Clone: CR3/43, DAKO, Cambridge-
shire, UK) and CD163 (1:2000, Monoclonal, Mouse Clone:
EDHu-1, AbD Serotec, Oxfordshire, UK) was carried out
to localise the regions of active chronic inflammation. The
following day, DAKO REAL Envision horseradish peroxid-
ase (HRP) solution (DAKO, Cambridgeshire, UK) was
applied for 30 minutes and diaminobenzidene chromo-
genic activation was performed. Immunolabelled sec-
tions were counterstained with haematoxylin (VWR
International, Leicestershire, UK), then coverslipped.
For double-labelled immunofluorescence, a similar proto-
col was applied except sections were incubated overnight at
4ºC in a primary antibody solution containing anti-phospho-
S6 Ribosomal proteins (ser240/244 or ser235/236). On the
Table 1 Pathology groups and clinical data
Pathology group Case Age of onset of
seizure (years)
Age at
resection
(years)/
Gender
Outcome Resection
site/Procedure
Main pathology features
in section
N = number of
cases
(Seizure type)
Epilepsy-lesional
pathology
HS N = 4 1 4 (PS, GS) 34 M SF Right ATL HS ILAE type I: neuronal loss
in CA1, CA4, gliosis, granule
cell dispersion; mossy fibre
sprouting confirmed in 3 cases.
2 6 (PS, GS) 43 F NSF Right ATL
3~ 1 (PS) 55 F NSF Left ATL
4 31 (PS, GS) 46 M NSF Left ATL
HS With dysmorphic
neurones n = 5
5 UK 30 F NSF Left ATL Hippocampal sclerosis (ILAE type I)
with dysmorphic neurones in CA4
and balloon cell glia in DG: mossy
fibre sprouting confirmed in 3 cases.
6 12 42 F NSF Right ATL
7 7 (PS, GS) 31 F SF ATL
8 25 (GS) 42 F SF Right ATL
9 14 (PS, GS) 54 F NSF Right ATL
FCDIIA N = 1 10~ 7 (PS, GS) 18 F NSF Right parietal resection Dysmorphic neurones; no
balloon cells.
FCDIIB N = 5 11~ UK (PS, GS) 26 M SF Right temporal lobectomy Dysmorphic neurones, cortical
dyslamination and balloon cells
12 11 months (PS) 24 F SF Left parietal resection
13~ 7 (GS) 34 F SF Right frontal resection
14 15 months (PS) 33 F NSF Right parietal resection
15 5 (PS, GS) 18 M NFS Right parietal resection
FCD IIIA N = 5 16 12 (PS) 54 F SF Right ATL Neuronal loss in outer cortical layers
with gliosis and reorganisation of
layer II neurones17 2 (PS) 34 M SF Right ATL
18 18 (PS, GS, SE) 44 M SF Left ATL
19 8 (PS, GS) 40 M SF Left ATL
20 3 (PS, GS) 19 F SF Left ATL
FCD IIIB N = 3 21 10 months (PS, GS) 27 F SF Left temporal lobectomy Cortex adjacent to a long-term
epilepsy associated tumour
(LEAT/DNT)22 6 (PS, GS) 23 M SF Right ATL
23 7 (PS) 31 F SF Temporal lobectomy
FCD IIID N = 3 24 3 (PS, GS) 18 F NSF Right hemispherectomy Cortical disorganisation adjacent
to an early infarct
25 4 (PS) 23 M NSF Left ATL
26 11 (PS, GS) 18 F NSF ATL
Rasmussen’s
Encephalitis N = 5
27 11 18/F NSF Right sided brain biopsy Active encephalitis* + gliotic
atrophic cortex
28 3 (FS, GS) 30 M SF Right hemispherectomy Active encephalitis* + neuronal
hypertrophy
29 14 (FS, GS, EPC) 18 M SF Temporal lobe resection and
hemispherectomy
Active encephalitis* + normal cortex
and atrophic cortex and frequent
dysmorphic neurones
30 UK 9 F NSF Left temporal lobe resection Burnt out encephalitis, atrophic cortex
31 UK UK NSF Cortical resection Burnt out encephalitis, atrophic cortex
Cortex adjacent
to Cavernoma
32 27 (FS) 30 M SF Right temporal lobe
resection
Cavernoma with reactive gliosis
including ‘balloon cell’ like glia
Control-non
lesional
Acute ICE
injury N = 5
11~ 12 (S, GS) 26 M SF Right temporal lobectomy Organising electrode track
cavity of 8 days
33 15 30 F SF Left ATL Organising electrode track
cavity of 8 days
10~ 7 (FS, GS) 18 F NSF Right parietal resection Organising electrode track
cavity of 8 days
12~ 11 months (FS) 24 F SF Left parietal resection Organising electrode track
cavity of 10 days
13~ 7 (GS) 34 F SF Right frontal resection Organising electrode track
cavity of 10 days
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Table 1 Pathology groups and clinical data (Continued)
Epilepsy: Paired
samples from
different regions
according to
intracranial
recordings. N = 4
34 6 (GS) 39M NSF Right frontal resection: No specific pathology- focal
inflammation
Sample 1. Ictal onset zone
Sample 2. Peripheral
samples in CUSA specimen
35 7 (PS, GS) 25 F SF Left frontal lobe resection No specific pathology
Sample 1. Seizure onset
zone
Sample 2. Frontal pole;
spreading of EEG activity
36 16 (PS) 33 M SF Right frontal lobe resection No specific pathology
Sample 1. Ictal onset zone
Sample 2. Inferior fronto-
orbital; spreading of activity
37 8 (PS,GS) 37 M SF Right frontal lobe resection Focal inflammation only
Sample 1. Ictal onset zone
Sample 2. Spreading of EEG
activity
Epilepsy: Pathology
negative
38 12 (GS) 18 M NSF Frontal lobe cortex Pathology negative
39 18 (PS, GS) 31M NSF
40 6 (PS, GS, SE) 34 M SF Temporal lobe cortex No pathology in temporal
lobe; HS in other sample
41 6 (PS, GS) 43 F SF
3~ 1 (PS) 55 F NSF
42 31 (PS, GS) 46 M NSF
43 UK 40M UK
44 6 (PS) 48 F NSF
45 7 (PS, GS) 48 M SF
Non-Epilepsy
Cortex N = 3
46 NA 37M NA Left temporal lobectomy Metastatic carcinoma
47 NA 30M NA Left temporal lobectomy Low grade oligo-astrocytoma
48 NA 74M NA Right temporal lobectomy High grade astrocytoma
ICE = Intracranial electrode, FCD = focal cortical dysplasia, HS = hippocampal sclerosis, DG = dentate gyrus, GS = generalised tonic clonic seizures, PS = partial of
focal seizures (no distinction made between complex and simple type), SE = status epilepticus, EPC = Epilepsy partialis continua, SF = completely seizure free at
follow up, NSF = not seizure free at follow up (includes nocturnal seizure and rare seizures/auras) [Follow up periods vary between 1 year to 15 years and status
taken at last follow up], ATL = anterior temporal lobectomy including hippocampectomy, DNT = dysembryoplastic neuroepithelial tumour, ICE = intracranial electrode
injury, CUSA = ultrasonic tissue aspirator, DG = dentate gyrus, UK = unknown. *Active encephalitis was determined by the presence of microglial nodules/neuronophagia
and lymphocytic infiltrates on H&E as well as HLADR and CD163 labelling. ~These cases had more than one lesion in different regions of the surgical resection.
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tor Laboratories Inc., Peterborough, UK) was applied for
30 minutes, before fluorescein-labelled antibody in tyramide
signal amplification (TSA) buffer (1:500, Perkin Elmer,
Massachusetts, UK) was applied for eight minutes. The
TSA system is a sensitive detection system used in pre-
vious human tissue studies (Thom et al., [26]). Sections
were thoroughly washed using phosphate buffer saline
(PBS), and then immersed in 0.9% hydrogen peroxide
solution for ten minutes before anti-doublecortin (DCX)
(1:250, Cell Signaling Technology Inc. USA), anti-CD34
(1:25, DAKO, Cambridgeshire, UK), anti-nestin (1:1000,
Abcam, Cambridge, UK), anti-Iba1 (1:1000, WAKO,
Osaka, Japan), anti-SMI32 (1:1000, Sternberger Mono-
clonals, Baltimore, MD, USA), anti-GFAPdelta (1:4000,
Abcam, Cambridge, UK) or anti-GFAP (1:100, DAKO,
Cambridgeshire, UK) diluted in DAKO antibody diluentwas applied overnight at 4°C. The next day, sections were
washed and incubated in species-specific peroxidase solu-
tion for 30 minutes before rhodamine-labelled antibody in
TSA buffer (1:500, Perkin Elmer, Massachusetts, USA)
was applied for eight minutes. After PBS washes, sections
were coverslipped using DAPI mounting medium (Vector
Laboratories Inc., Peterborough, UK).
The cellular staining and distribution was assessed
qualitatively using brightfield (Nikon Eclipse 80i), epi-
fluorescence (Zeiss Axio Imager Z2), and confocal laser
scanning microscopes (LSM-Meta 710, Zeiss, Germany)
Results
HS ILAE Type 1 with dysmorphic neurones
In these cases with histological features as previously re-
ported [15] (Figure 1A), strong labelling of hypertrophic
neurones in CA4 and dentate gyrus was observed using
Figure 1 pS6 in HS ILAE type 1 with (A-J) and without (K-L) dysmorphic changes. HS ILAE type 1 with dysmorphic changes (A-J) (A) The
dentate gyrus in a case with ILAE HS type 1 and additional glassy balloon-like astroglial cells on H&E which show membranous positivity for
CD34 (inset). (B) pS6 235/236 labelling of hypertrophic CA4 neurones and (C) in the granule cell layer was noted in HS cases with dysplasia features;
inset shows co-localisation of labelling in a proportion of cells with the two pS6 antibodies. (D) pS6 235/236 also labelled small immature cells with
bipolar or multipolar processes including in the basal layer of the dentate gyrus (D) as well as through the dentate gyrus (E). Co-localisation
between doublecortin (DCX) and pS6 was noted in some of these small cells in the dentate gyrus (F) as well as with nestin (G); in addition
both pS6 markers co-labelled a proportion of small multipolar cells in HS. (I) With pS6 240/244 prominent labelling of horizontal cells in the
stratum moleculare of the hippocampus, in addition to more distinct labelling of pyramidal cells through hippocampal subfields was noted.
HS ILAE type 1: Intense labelling of CA4 neurones but the the granule cells were more variably negative (K) or positive (L) with pS6 240/244.
White arrowheads in all images indicate double-labelled cells. Bar in A, C, D, E, F, G, H and J equivalent to approximately 35 microns and in B, I, K
and L approximately 50 microns.
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labelling of other neuronal cells, particularly granule
cells (Figure 1B-D). Prominent labelling of small, bipolar
and multipolar cells was striking in the dentate gyrus
and CA4 (Figure 1D,E) and to a lesser extent in other
subfields and white matter. In one case (case 6), promin-
ent labelling of such cells located along the basal layer of
the granule cell layer was observed (Figure 1D). In
addition, labelling for pS6 was also noted in large CD34-
positive balloon-like cells (Figure 1A) in the dentate gyrus.
Double labelling immunofluorescent studies showed the
co-localisation of pS6 with DCX (Figure 1F), nestin, aswell as pS6 (ser 240/244) with pS6 (ser235/236) in
some of the small cells, particularly in the granule cell
layer (Figure 1H).
In comparison, anti-pS6 (ser240/244) showed more
prominent neuronal labelling, including horizontal cells
in the molecular layer (reminiscent of Cajal-Retzius cells)
(Figure 1I) and pyramidal cells in CA1-3 (Figure 1J). In-
tense anti-pS6 (ser240/244) immunoreactivity was also
noted in residual hypertrophic CA4 cells (Figure 1C, inset).
Although less prominent than with anti-pS6 (ser235/236),
the anti-pS6 (ser240/244) antibody also labelled small,
multipolar cells in the hippocampus, and co-expression
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(Figure 1G) and DCX in the dentate gyrus.HS ILAE type 1
Scattered residual CA4 neurones were also intensely
labelled with anti-pS6 (ser235/236), although labelling
with this marker was more prominent in small, multipolar
cells in CA4, the subgranular zone and CA1. Intense and
frequent labelling of neurones from the subiculum to CA4
was more consistently seen with anti-pS6 (ser240/244)
(Figure 1K). The granule cell layer was more-often
immuno-negative with both pS6 antibodies (Figure 1K),Figure 2 pS6 in FCD subtypes. FCD II: (A) Intense labelling was confirme
highlighting the tigroid appearance of the cytoplasm (B). Dysmorphic neu
cytoplasm of balloon cells appeared somewhat weaker. (D) Double labellin
some balloon cells co-labelling with DCX (arrowhead, inset); small DCX bip
DCX-positive cell processes around a pS6-positive balloon cell (inset) was al
loss demonstrated with NeuN labelling and clusters of neurones in layer II acco
the residual neurones in layer II with pS6 ser 235/6 (G) and pS6 ser 240/244 (H
240/244 with GFAPdelta isoform in the cortex (I) and white matter (J) a
perivascular regions (K), as well as focally between DCX-positive small c
of scattered cortical neurones in adjacent dyslaminar cortex, as well as n
the small tumour cells (M). FCDIIId: Disrupted cortex adjacent to an old
pattern of pyramidal cells (N); inset shows prominent labelling of astroglial ce
A, B, C, D, I, J, K and L equivalent to approximately 35 microns, in e,f,g,h andalthough intense labelling of granule cells, including
dispersed cells, was noted in some cases (Figure 1L).
FCD II
In the single case with FCDIIa pathology, prominent label-
ling of DN was seen with both pS6 antibodies, highlight-
ing the region of dysplasia (Figure 2A), with less intense
labelling of reactive glia in the region of the dysplasia; la-
belling of neurones in the adjacent non-dysplastic cortex
was, however, also noted. In five cases of FCDIIb, DN
showed a striking tigroid cytoplasmic labelling pattern
with both pS6 markers, sometimes condensing in the peri-
nuclear zone (Figure 2B,C). BC showed immunopositivityd in dysmorphic neurones in FCDIIa and FCD IIb (B) as anticipated,
rones were also intensely positive with pS6 235/6 (C), although the
g of pS6 with DCX confirmed the balloon cells as pS6 positive, with
olar cells were not always pS6 labelled (arrow) and wrapping of a
so noted. FCD IIIa: (E) FCD type IIIa (adjacent to HS) with laminar neuronal
mpanied by mark superficial cortical gliosis (F); in these cases labelling of
) was noted. Double labelling studies confirmed co-localisation of pS6
nd between nestin and pS6 235/6 in small glial cells particularly in
ells and pS6 235/236 (L). FCD IIIb: pS6 highlighted intense labelling
eurones trapped within the tumour (inset), but negative labelling of
perinatal infarct in this case showed a prominent ‘tramline’ labelling
lls in the region of chronic cortical scarring in an FCD IIId case. Bar in
m to 50 microns and in n to 100 microns.
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tensely labelled than the DN (Figure 2C). In addition, la-
belling of small glial-like cells (multipolar and bipolar
cells) was noted in the region of dysplasia, and in morpho-
logically normal neurones in the adjacent cortex. Double
labelling with anti-pS6 (ser 235/236) and DCX showed
the co-labelling of some BC, although many small DCX-
positive cells were not labelled (Figure 2D).
FCD III
These cases were characterised by neuronal loss, gliosis and
associated reorganisation of cortical layers II and III with
mal-orientated and clustered neurones [26,1] (Figure 2E,F).
Prominent immunoreactivity of the residual horizontal
neuronal clusters in layer II for both pS6 antibodies was
noted in two of five cases (Figure 2G,H). Labelling was
evident in glial cells in the superficial cortex (Figure 2G)
and of scattered pyramidal cells throughout the deeper
cortical layers (Figure 2H) and glial cells in the white mat-
ter around vessels. Double labelling showed co-expression
of pS6 markers with GFAPdelta in small cells located in
the superficial cortex and in the white matter (Figure 2I,J)
and with nestin, which was prominent in perivascular
regions (Figure 2K). There was also evidence of co-
localisation of pS6 and DCX in occasional small cells in
the superficial cortex (Figure 2L). The three cases of DNT
with adjacent cortex showing dyslamination at the tumour
margin (FCDIIIb) showed strong labelling with pS6 of
cortical neurones entrapped within the tumour, with
tumoural oligodendrocyte-like cells strikingly immuno-
negative (Figure 2M). The adjacent cortex showed la-
belling of glial cells in layer I and in occasional cortical
neurones (Figure 2M) but the pattern and distribution,
in both tumour and peri-tumoral cortex, differed to
that observed with CD34 labelling. In three cases of
FCDIIId (cortical dyslamination/disorganisation adja-
cent to an early infarct), intense labelling of astrocytic
cells in the region of the old cortical scar was prominent
(Figure 2N, inset). Labelling of scattered neurones in the
adjacent cortex was seen in all cases and with a prominent
‘tramline’ pattern of labelling of pyramidal cells in layers
III and V in one case (case 24) with pS6 (ser240/244)
(Figure 2N). A single case of a cavernoma showed prom-
inent pS6 labelling of reactive glia adjacent to the vascular
lesion with both antibodies.
RE
The stage of inflammatory activity varied between the
five cases (Table 1). In two cases with extensive tissue
resections, areas with active inflammation alternated
with stretches of cortex showing chronic scarring and
quiescent inflammation as well as regions of more nor-
mal appearing cortex; the presence of hypertrophic, dys-
morphic neurofilament-positive neurones was evident inthe abnormal cortex. The presence of focal, active en-
cephalitis was confirmed with the microglial marker,
HLADR (for activated microglia and macrophages),
which showed increased numbers in the region of more
active inflammation (Figure 3A). CD163 labelling, which
shows macrophages of haemopoietic origin, also showed
scattered, immunopositive, rod-like cells in these regions
(Figure 3A, inset) compared to less damaged cortex,
where CD163 positive cells were limited to the perivas-
cular spaces. In the regions of active encephalitis, there
was evidence of increased labelling with both pS6 anti-
bodies (Figure 3B,C). pS6 (ser 240/244) particularly
highlighted DN, whose neuronal nature was confirmed
by double labelling for SMI32 (Figure 3D). pS6 (ser235/
236) showed prominent labelling of small multipolar
(Figure 3E) and bipolar cells (Figure 3F) in the damaged
cortex; these were of similar morphology to those ob-
served in the dentate gyrus in HS. Double labelling stud-
ies suggested the majority of pS6-positive small cells
were not GFAP-expressing astrocytes (Figure 3G); but
rather showed more frequent co-localisation with Iba1
(Figure 4H), nestin (in both the cortex and white matter)
(Figure 4L) and to a lesser extent, with DCX (Figure 4L
inset). pS6 (ser240/244) labelling of cortical neurones,
including pyramidal cells in all cortical layers, was also
noted in the adjacent better-preserved cortex in larger
resections.
Non-lesional cases and controls
In the five patients with acute cortical injuries following
depth electrode studies, tracks lined by reactive inflam-
matory and granulation tissue were identified in the tissue
resections. Prominent labelling with both pS6 antibodies
highlighted the injury site with labelling of cell types of
mixed morphologies including neurones, astrocytes, mac-
rophages around the electrode cavity as well as vascular
endothelium (Figure 4A). In addition, more widespread la-
belling of cortical neurones was also noted in some cases.
Four patients with paired frontal tissue samples from sep-
arate sites according to intracranial electroencephalo-
graphic activities (cases 34–37, Table 1) showed no
specific pathology, apart from mild inflammation. In
one case (case 34), there were clear qualitative differ-
ences in the density of positive neuronal, glial and vas-
cular labelling with both pS6 antibodies between the
sample pairs (Figure 4B,C), but there were no clear dif-
ferences between the samples in the three other cases.
In seven non-lesional temporal lobe cortical resections
adjacent to HS (cases 40–45, Table 1), scattered cor-
tical pyramidal cells were intensely labelled with both
pS6 markers. A greater proportion of neurones were
positive with pS6 (ser240/244) than pS6 (ser235/236),
particularly in layers III and V, imparting a ‘tramline’
labelling pattern in some cases (Figure 4D). Striking
Figure 3 Rasmussen’s encephalitis. (A) Areas of active encephalitis and cortical scarring highlighted with increased numbers of HLADR-positive
microglia/macrophages, as well as interstitial rod-like CD163-positive microglia cells (inset). (B) On adjacent sections, labelling with pS6 235/236
showed a similar distribution of cellular labelling as well as with pS6 240/244 (C). (D) pS6 240/244 highlighted many of the enlarged dysmorphic
neurones in RE cases, as confirmed with co-labelling with neurofilaments (inset). (E) pS6 236/26 demonstrated labelling of smaller glial cells as
well as (F) bipolar rod shape cells. Double labelling studies in RE cases confirmed the majority of pS6 labelled cells were not GFAP-positive
astroglia (G) but co-labelled with populations of iba1-positive cells (microglial marker) (H), nestin and doublecortin (inset) (I) positive cells.
Bar in A, B, C equivalent to approximately 100 microns, in d approximately 50 microns and E, F, G, H, I approximately 30 microns.
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cortex in other cases with pS6 (ser235/236) (Figure 4E). La-
belling of small multipolar glia-like cells was more
prominent with pS6 (ser235/236) in the white matter
around vessels, in layer I and the subpial region (Figure 4F).
In the pathology-negative frontal cortical resections (cases
38,39), variable patchy cortical neuronal staining ofmoderate intensity was also noted with pS6 (ser240/244 >
ser235/236), but a tramline pattern of neuronal labelling
was not apparent in frontal lobe cortex; labelling of small
multipolar glial-like cells, particularly in the perivascular
white matter, was also present. In the cortex from three
control patients without epilepsy undergoing cortical
resection for the treatment of tumours, occasional
Figure 4 Non-lesional epilepsy and control groups. (A) Intense labelling of morphologically different cells types, including macrophages and
multipolar cells (inset), around an organising intracranial electrode track mark. (B and C) Paired samples from regions of different ictal activity,
based on intracranial monitoring: (B) is from case 34, sample 1 (ictal onset zone) where less pS6 labelling was seen with both markers (illustrated
here with pS6 240/244) compared to (C) sample 2 which represented less active/seizure spreading zone where more pS6 labelling of small cells
was observed as well as neuronal cells (inset). (D) Temporal lobe cortex with no specific pathology, adjacent to HS, where prominent ‘tramline’
labelling of cortical neurones was observed with pS6 240/244. (E) Another pathologically normal temporal lobe in epilepsy with a prominent
perivascular labelling pattern of neuronal cells with pS6 235/236 (arrowhead) and (F) labelling of small glial like cells around vessels in the white
matter and inset in the subpial layer (inset). Bar in A, B, C, E, F equivalent to approximately 50 microns and in d to 100 microns.
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cortical neurones.
Discussion
Using pS6 immunoreactivity as evidence of mTOR path-
way activation [27,3,6,4], we have demonstrated labelling
of DN in a range of mainly acquired epilepsy-associated
pathologies in addition to the well-established labelling
that occurs in FCDIIb [3,6]. We have also shown pS6 ex-
pression in small, immature cell types as well as more
normal neurones in epileptogenic-lesional and pathology-
negative epilepsy surgical resections. The mTOR pathway
is a central regulator of several vital functions relating to
cell growth, proliferation and survival [8]. It was initially
recognised as being pathologically activated in TSC and
FCDIIb [3,6] and subsequently in related malformative
lesions primarily characterised by abnormal neuronal
growth, such as hemimegalencephaly and gangliogliomas,with pS6 coming to be regarded as a biomarker of these
‘mTORopathies’ [4,5]. Moreover, mTOR pathway activa-
tion has been reported as less evident or absent in FCD I
or histologically-normal cortex in epilepsy [3,28,29].
We show that pS6 is not a specific marker for the cyto-
pathology of FCD IIb or TSC in epilepsy, but more
generally highlights dysmorphic cells and immature
cells in epilepsy.
The mTORC1 component pathway of mTOR is the
rapamycin-sensitive pathway, leading to growth-promoting
conditions and increased rates of protein synthesis. The
best characterized downstream targets are the eukaryotic
initiation factor 4E binding protein 1 (4E-BP1) and the
p70 ribosomal S6kinase 1 (S6K1) [30,8,4]. As pS6 is also
phosphorylated by this kinase in an mTOR-independent
manner [31], we used two antibodies recognising mTOR
specific as well as mTOR non-specific phosphorylation
sites, as employed in previous studies [6,21], although we
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cases in this study to further validate specificity. Although
we noted a different range of cell expression with these
two antibodies in all pathologies, co-localisation of labelling
was shown in a proportion of cells. mTORC1 is normally
regulated in varied physiological conditions that influence
growth factors and cell energy status, through PI3K-AKT,
PDK1, PTEN and other upstream signals [8,31]. In TSC,
mutations occur in TSC1 or TSC2 which negatively regu-
late mTORC1 but the mechanism of mTOR pathway acti-
vation in sporadic FCDIIb remains less well understood,
with no identified pathogenic mutations. Recently Human
Papilloma Virus type 16 has been detected specifically in
FCDIIb as a potential acquired cause of TORC1 activation
[5,32]. Interestingly, mutations have been recently shown
in an mTORC1 interacting protein, DEPDC5, in patients
with malformations and epilepsy, as well as non-lesional
epilepsy [33] and mTOR mutations have also been de-
tected in epileptic encephalopathies [34] implicating this
pathway may be involved in varied epilepsies.
The pathological diagnosis in FCDIIb is usually uncon-
troversial with standard histological stains [35]. pS6 label-
ling of BC with immunohistochemistry may be employed
as an adjunct test, highlighting these abnormal cell popu-
lations [3,6,11]. This was confirmed in our series, although
we noted that labelling of BC was often less pronounced
than DN labelling [29]. In acquired epilepsy pathologies,
dysplasia-like features may be seen, including neuronal
hypertrophy with pronounced neurofilament positivity,
and enlarged and hyperplastic glial cells with CD34 ex-
pression, simulating a superimposed dysplasia, which to-
gether presents a diagnostic challenge. Several reports,
including cases from our own surgical series, have noted
HS accompanied by hypertrophic neurones in CA4
[16,14] or dysmorphic dentate gyrus neurones associated
with prominent CD34-positive BC-like glia [12,13,15]. pS6
labelling in five such cases highlighted these abnormal
neuronal cells in CA4 and the dentate gyrus. Previous re-
ports of pS6 expression in dentate granule cells in HS
noted labelling in a minority of cases, even in the presence
of dispersion [20,21], however when present it correlated
with increased neuronal size [20]. In rodent models of HS,
pS6 has been reported in the granule cells at six hours
following kainate-induced seizures [20]. Interestingly,
when PTEN was selectively deleted in granule cells
(with resulting hyperactivation of mTOR), spontaneous
epilepsy, granule cell hypertrophy and mossy fibre
sprouting occurred [36]. In the present study, although
we also noted inconsistent labelling of granule cells and
other neurones with pS6 across HS cases, when present,
it mainly correlated with abnormal or hypertrophic
neuronal changes, which may in turn be significant to
pro-epileptogenic mechanisms in addition to cytopatho-
logical alterations.In RE, the co-existence of an FCD-like pathology is well
recognised [18,19]. In such cases, the main differential
diagnosis includes FCD type II with secondary or super-
imposed inflammatory changes. However, the histological
diagnosis of RE is made in the overall context of progres-
sive uni-hemispheric radiological changes and lateralising
neurological symptoms [37]. In cases which met criteria
for RE in our series, scattered neurones with hypertrophy
and dysmorphism were observed integrated within in-
flamed or atrophic cortex and we noted intense labelling
of these DN with pS6 antibodies. Similarly, pS6 also
labelled mildly enlarged, abnormally orientated layer II
neurones in a proportion of FCD IIIa cases, entrapped
neurones within DNT subtypes of LEAT (but not the
tumoural component, as also in a recent study [27]) as
well as neurones in FCDIIId. These findings all indicate
pS6 as more ubiquitously present in DN in a range of
epilepsy-associated pathologies. Furthermore, our studies
indicate that pS6 labelling cannot reliably discriminate
FCDII from RE with associated dysplasia.
Labelling neuroglial cell populations with pS6 in epi-
lepsy pathologies, including FCD, has been recognised
[29]. In HS for example, prominent and sustained label-
ling of astrocytes and microglia in the sclerotic hippo-
campus, with a relative reduction of neuronal staining
was reported [21]. In that study, as little astroglial pS6
expression was identified in chronic neocortical scars, it
was suggested that mTOR activation in hippocampal as-
trocytes was of relevance to epileptogenesis [21]. A simi-
lar study of HS in mTLE, also commented on intense
labelling of astrocytes in hippocampal subfields and the
dentate gyrus as well as in rodent models after 5 days of
seizure induction [20]. Again, the interpretation was that
over-activation of mTOR in astroglia in the more chronic
phases of HS may nurture a local pro-epileptogenic
microenvironment. In addition to HS cases, we noted pS6
labelling of astroglial cells in other pathologies including
adjacent to electrode track injuries, one cavernoma with
adjacent cellular gliosis as well as the long-standing glio-
sis associated with perinatal infarcts and FCDIIId. In
pathology-negative epilepsy controls, only focal label-
ling of glial cells was seen, with minimal labelling in
non-epilepsy controls. This observation of sustained
pS6 labelling of astrocytes, localising to epileptogenic
pathologies, would support the hypothesis of a role in
promoting pro-epileptogenic glial cell activity. We also
showed pS6 labelling of microglial cell types in RE and
in macrophages around organising electrode tracks.
mTOR, through IL-2 induction of T-cell proliferation
[38], can influence inflammatory processes [39]; in
turn, mTORC1 activation is regulated by inflammatory
activity, for example through cytokines such as TNFα
[8]. A correlation was recently shown between pS6 and
inflammatory pathway activation in LEATs [27]. Our
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the mTOR pathway and chronic inflammatory pro-
cesses in RE which could be further investigated.
It is known that mTOR impacts on normal stem cell
development and proliferation [30] and the maintenance
of neural stem cells and progenitor cells [40]. We were
interested therefore to explore mTOR activation in im-
mature cell types, including in the dentate gyrus, an
established neurogenic niche which may be influenced
by seizures in adulthood [41]. A previous study of pS6 in
HS/mTLE did not confirm pS6 in NG2-positve progeni-
tor cells [21]. We have recently reported immature,
DCX-positive bipolar cells in the dentate gyrus in HS in
adults (Thom et al. 2014 In press, Psychological Medi-
cine). In this present study we observed pS6 expression
in these immature cell types, as well as in morphologic-
ally similar DCX-positive cells in RE cases. Similarly, im-
munostaining for nestin and GFAPdelta, developmentally
regulated intermediate filaments [42], highlighted popula-
tions of immature glia in CA4 and the dentate gyrus in
HS, as previously reported [43]. We have also recently
identified nestin-positive glial cells in epilepsy cortical and
white matter resections as representing a transient prolif-
erative cell population, important in normal brain repair
processes [24]. In this current study we also noted mTOR
activation of similar immature cell types in HS as well as
FCD III cases, which could highlight a functional role in
the patho-aetiology of acquired epilepsy pathologies.
We aimed to address any differences in pS6 expression
in direct relation to seizure activity by studying separate
tissue samples with no specific pathologies but from
areas of differing electrical activity based on intracranial
recordings prior to the surgery. We were not able to
confirm consistent differences in pS6 neuronal-glial la-
belling between samples. Although we did not see cav-
ities relating to subdural grid placement or electrode
track marks in these paired samples, we cannot exclude
that nearby reactive inflammatory processes influence
pS6 expression and mask any differences related to
disease activity. Furthermore, pS6 expression was previ-
ously reported to be virtually absent in pathology-
negative cortex in epilepsy [3] as well as in more recent
studies [27,44] although labelling was noted in non-
sclerotic hippocampal neurones [21]. We confirm some
degree of pS6 neuronal and glial labelling in all pathology-
negative epilepsy cases as well as non-epilepsy controls.
There is experimental evidence implicating dysregulation
of mTOR more generally in the processes of epileptogen-
esis, including acquired pathologies [45,7], dysregulation
being also detectable in the absence of a pathological lesion
[46]. mTOR inhibitors, such as rapamycin and its ana-
logues, have been shown experimentally to ameliorate
seizures and reverse potential pro-epileptogenic cellular
alterations [47-49], for example through inhibition ofmossy fibre sprouting [45,50,51]. mTOR inhibitors have
recently been approved for the treatment of some TSC
lesions with success in reversal of growth of lesions
[45,7,52,53]. Experimental studies also show that mTOR
inhibition has anti-epileptogenic effects in TSC, al-
though the precise mechanisms are unknown [39]. Our
current findings suggest that mTOR dysregulation may
well be more generally implicated in pathogenesis of
varied acquired lesions in focal epilepsies, particularly
in the presence of dysmorphic cytopathology; the
causes of this deserve further investigation. If more evi-
dence emerges of the anti-epileptogenesis and seizure-
control capacity of mTOR modulators, it may be that such
therapies will find application across a broader range of
epilepsies.
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